Why the study?
Device therapy presents an important nonpharmacological approach, but its impact and potential needed investigation for optimizing treatment in patients with AF and HFpEF.
Do device-based interventions improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction?
Do device-based interventions improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction?
Device therapies, including pacing strategies, contractility modulation, and structural interventions, offer promising nonpharmacological options to improve symptoms and cardiac function in the complex AF and HFpEF population.
Answers are grounded in this paper and cite their sources.
Suggests device therapies may aid symptoms in AF-HFpEF; leaves open need for RCTs on outcomes before practice change.
Device therapy is a nonpharmacological approach that presents a crucial advancement for managing patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). This review investigated the impact of device-based interventions and emphasized their potential for optimizing treatment for this complex patient demographic. Cardiac resynchronization therapy, augmented by atrioventricular node ablation with His-bundle pacing or left bundle-branch pacing, is effective for enhancing cardiac function and establishing atrioventricular synchrony. Cardiac contractility modulation and vagus nerve stimulation represent novel strategies for increasing myocardial contractility and adjusting the autonomic balance. Left ventricular expanders have demonstrated short-term benefits in HFpEF patients but require more investigation for long-term effectiveness and safety, especially in patients with AF. Research gaps regarding complications arising from left ventricular expander implantation need to be addressed. Device-based therapies for heart valve diseases, such as transcatheter aortic valve replacement and transcatheter edge-to-edge repair, show promise for patients with AF and HFpEF, particularly those with mitral or tricuspid regurgitation. Clinical evaluations show that these device therapies lessen AF occurrence, improve exercise tolerance, and boost left ventricular diastolic function. However, additional studies are required to perfect patient selection criteria and ascertain the long-term effectiveness and safety of these interventions. Our review underscores the significant potential of device therapy for improving the outcomes and quality of life for patients with AF and HFpEF.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: